Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for the treatment of advanced renal cell carcinoma, available on the Cancer Drugs Fund.
List view / Grid view
Filter the results
The recommendation of Adcetris (brentuximab vedotin) represents the first new frontline therapy for systemic anaplastic large cell lymphoma (sALCL) in several decades.
The cervical dysplasia drug-device product, APL-1702 (Cevira®), offers an alternative to surgery and has been approved to start a clinical trial in China and several other countries.
The FDA has given approval to Phesgo for injection under the skin to treat HER2-positive breast cancer, meaning it can be administered at home by a healthcare professional.
Following the successful treatment of a COVID-19 patient with ARDS using ruxolitinib, Germany is set to begin clinical trials to test the drug.
Pharma executives are committed to bringing drugs to market to improve the lives of patients but is the industry too introspective to be truly innovative?
After three clinical trials showing its efficacy, NICE has recommended Rozlytrek (entrectinib) as treatment for non-small cell lung cancer (NSCLC).
Treating COVID-19 patients with respiratory distress with acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor reduced inflammation and improved their breathing within three days.
Scientists have designed and synthesised chains of molecules for the purpose of drug delivery with a precise sequence and length to protect DNA nanostructures from degradation under biomedically relevant conditions.
Researchers reveal dose-adjusted (DA) EPOCH-R chemotherapy regimen was effective across all ages of Burkitt lymphoma patients in a Phase II clinical trial.
Lynparza’s approval was based on results from a Phase III clinical trial in which it improved overall survival and progression-free survival in patients with certain prostate cancers.
The FDA has approved Tabrecta (capmatinib) for patients with metastatic non-small cell lung cancer whose tumours have a mutation that leads to MET exon 14 skipping.
A new potential platform for drug delivery has been created by researchers using attentuate diptheria toxin, which can enter cells and escape the endosome.
Scientists have developed a protocol for encapsulating antibodies in an ultrasound-sensitive drug carrier for targeted drug delivery.
Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.